AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2024
May 24, 2024
32883_dirs_2024-05-24_79148008-147f-4f69-8bb1-71e85e17dd3c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2024-05-22
Reporting Person: Cittadine Andrew (Chief Operating Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-05-22 | Stock Options | $0.6146 | A | 25000 | Acquired | 2034-05-22 | Common Stock (25000) | Direct |
Footnotes
F1: Options vest 6/48ths on November 21, 2024 and 1/48th per month thereafter.
More from Monopar Therapeutics
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 1
Annual Report
2026
Mar 27
Director's Dealing
2026
Mar 4
Board/Management Information
2026
Mar 2